Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Tuberculosis | Research

Evaluation of Mycobacterium tuberculosis specific antigen-stimulated CD27CD38+IFN-γ+CD4+ T cells for discrimination of active tuberculosis

Authors: Yong Fang, Na Wang, Liang Tang, Xiao-Jun Yang, Yuan Tang, Lin Li, Wen-Fei Wu, Bo Su, Wei Sha

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

Active tuberculosis (ATB) originates from primary Mycobacterium tuberculosis (MTB) infection or reactivation of latent tuberculosis. Besides bacteriological examination, MTB-reactive immunocytes detection can be an alternative testing for discrimination of active tuberculosis. The purpose of this study is to investigate the accuracy of peripheral blood CD27CD38+IFN-γ+CD4+T cells in ATB diagnosis.

Methods

This prospective diagnostic accuracy study was conducted at Shanghai Pulmonary Hospital between January 2019 and December 2021. Patients with ATB, non-tuberculosis mycobacterium infection (NTM), latent tuberculosis infection (LTBI), other respiratory diseases (OD), and healthy individuals (HC) were enrolled. The accuracy of CD27CD38+IFN-γ+CD4+/CD4+ and other phenotypic markers for ATB diagnosis was assessed.

Results

A total of 376 patients (237 ATB, 38 LTBI, 8 NTM, 50 OD, and 43 HC) were enrolled. The ratios of CD4+IFN-γ+CD27 and CD4+IFN-γ+CD27CD38+ profiles in CD4+IFNγ+ cells and the ratios of CD4+IFN-γ+CD38+, CD4+IFN-γ+CD27, and CD4+IFN-γ+CD38+CD27 profiles in CD4+ cells in the ATB group were significantly higher than in the other groups. The area under the curve (AUC) of CD27CD38+IFN-γ+CD4+/CD4+ for the diagnosis of ATB was the highest, with a value of 0.890. With the optimal cutoff value of 1.34 × 10–4, the sensitivity and specificity of CD27CD38+IFN-γ+CD4+/CD4+ for ATB diagnosis was 0.869 and 0.849, respectively.

Conclusion

CD27CD38+IFN-γ+CD4+/CD4+ might be a potential biomarker for active tuberculosis diagnosis.
Literature
1.
go back to reference GBDT Collaborators. The global burden of tuberculosis: results from the global burden of disease study 2015. Lancet Infect Dis. 2018;18(3):261–84.CrossRef GBDT Collaborators. The global burden of tuberculosis: results from the global burden of disease study 2015. Lancet Infect Dis. 2018;18(3):261–84.CrossRef
2.
go back to reference Grobusch MP, Kapata N. Global burden of tuberculosis: where we are and what to do. Lancet Infect Dis. 2018;18(12):1291–3.CrossRefPubMed Grobusch MP, Kapata N. Global burden of tuberculosis: where we are and what to do. Lancet Infect Dis. 2018;18(12):1291–3.CrossRefPubMed
3.
go back to reference World Health Organization. Global tuberculosis report 2018. World Health Organization. WHO/CDS/TB; 2018. World Health Organization. Global tuberculosis report 2018. World Health Organization. WHO/CDS/TB; 2018.
4.
5.
go back to reference Cui X, Gao L, Cao B. Management of latent tuberculosis infection in China: exploring solutions suitable for high-burden countries. Int J Infect Dis. 2020;92S:S37–40.CrossRefPubMed Cui X, Gao L, Cao B. Management of latent tuberculosis infection in China: exploring solutions suitable for high-burden countries. Int J Infect Dis. 2020;92S:S37–40.CrossRefPubMed
7.
go back to reference Theron G, et al. Xpert MTB/RIF results in patients with previous tuberculosis: can we distinguish true from false positive results? Clin Infect Dis. 2016;62(8):995–1001.CrossRefPubMedPubMedCentral Theron G, et al. Xpert MTB/RIF results in patients with previous tuberculosis: can we distinguish true from false positive results? Clin Infect Dis. 2016;62(8):995–1001.CrossRefPubMedPubMedCentral
8.
go back to reference Theron G, et al. False-positive Xpert MTB/RIF results in retested patients with previous tuberculosis: frequency, profile, and prospective clinical outcomes. J Clin Microbiol. 2018;56(3):e01696-17.CrossRefPubMedPubMedCentral Theron G, et al. False-positive Xpert MTB/RIF results in retested patients with previous tuberculosis: frequency, profile, and prospective clinical outcomes. J Clin Microbiol. 2018;56(3):e01696-17.CrossRefPubMedPubMedCentral
9.
go back to reference Nicol MP. Xpert MTB/RIF: monitoring response to tuberculosis treatment. Lancet Respir Med. 2013;1(6):427–8.CrossRefPubMed Nicol MP. Xpert MTB/RIF: monitoring response to tuberculosis treatment. Lancet Respir Med. 2013;1(6):427–8.CrossRefPubMed
10.
go back to reference Kwiatkowska S. The IGRA tests: where are we now? Pneumonol Alergol Pol. 2015;83(2):95–7.PubMed Kwiatkowska S. The IGRA tests: where are we now? Pneumonol Alergol Pol. 2015;83(2):95–7.PubMed
11.
go back to reference Tang F, et al. Key determinants of misdiagnosis of tracheobronchial tuberculosis among senile patients in contemporary clinical practice: a retrospective analysis. World J Clin Cases. 2021;9(25):7330–9.CrossRefPubMedPubMedCentral Tang F, et al. Key determinants of misdiagnosis of tracheobronchial tuberculosis among senile patients in contemporary clinical practice: a retrospective analysis. World J Clin Cases. 2021;9(25):7330–9.CrossRefPubMedPubMedCentral
12.
13.
go back to reference Rodriguez-Takeuchi SY, Renjifo ME, Medina FJ. Extrapulmonary tuberculosis: pathophysiology and imaging findings. Radiographics. 2019;39(7):2023–37.CrossRefPubMed Rodriguez-Takeuchi SY, Renjifo ME, Medina FJ. Extrapulmonary tuberculosis: pathophysiology and imaging findings. Radiographics. 2019;39(7):2023–37.CrossRefPubMed
14.
go back to reference Cherian JJ, et al. Treatment outcome of extrapulmonary tuberculosis under revised national tuberculosis control programme. Indian J Tuberc. 2017;64(2):104–8.CrossRefPubMed Cherian JJ, et al. Treatment outcome of extrapulmonary tuberculosis under revised national tuberculosis control programme. Indian J Tuberc. 2017;64(2):104–8.CrossRefPubMed
17.
go back to reference Dinur-Schejter Y, et al. The clinical aspect of adaptor molecules in T cell signaling: lessons learnt from inborn errors of immunity. Front Immunol. 2021;12: 701704.CrossRefPubMedPubMedCentral Dinur-Schejter Y, et al. The clinical aspect of adaptor molecules in T cell signaling: lessons learnt from inborn errors of immunity. Front Immunol. 2021;12: 701704.CrossRefPubMedPubMedCentral
18.
go back to reference Hwang JR, et al. Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development. Exp Mol Med. 2020;52(5):750–61.CrossRefPubMedPubMedCentral Hwang JR, et al. Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development. Exp Mol Med. 2020;52(5):750–61.CrossRefPubMedPubMedCentral
19.
go back to reference Adekambi T, et al. High frequencies of caspase-3 expressing Mycobacterium tuberculosis-specific CD4(+) T cells are associated with active tuberculosis. Front Immunol. 2018;9:1481.CrossRefPubMedPubMedCentral Adekambi T, et al. High frequencies of caspase-3 expressing Mycobacterium tuberculosis-specific CD4(+) T cells are associated with active tuberculosis. Front Immunol. 2018;9:1481.CrossRefPubMedPubMedCentral
20.
go back to reference Petruccioli E, et al. Assessment of CD27 expression as a tool for active and latent tuberculosis diagnosis. J Infect. 2015;71(5):526–33.CrossRefPubMed Petruccioli E, et al. Assessment of CD27 expression as a tool for active and latent tuberculosis diagnosis. J Infect. 2015;71(5):526–33.CrossRefPubMed
21.
go back to reference Sallusto F, Lanzavecchia A. Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity. Eur J Immunol. 2009;39(8):2076–82.CrossRefPubMed Sallusto F, Lanzavecchia A. Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity. Eur J Immunol. 2009;39(8):2076–82.CrossRefPubMed
22.
go back to reference Aksoy P, et al. Regulation of SIRT 1 mediated NAD dependent deacetylation: a novel role for the multifunctional enzyme CD38. Biochem Biophys Res Commun. 2006;349(1):353–9.CrossRefPubMed Aksoy P, et al. Regulation of SIRT 1 mediated NAD dependent deacetylation: a novel role for the multifunctional enzyme CD38. Biochem Biophys Res Commun. 2006;349(1):353–9.CrossRefPubMed
23.
go back to reference Aksoy P, et al. Regulation of intracellular levels of NAD: a novel role for CD38. Biochem Biophys Res Commun. 2006;345(4):1386–92.CrossRefPubMed Aksoy P, et al. Regulation of intracellular levels of NAD: a novel role for CD38. Biochem Biophys Res Commun. 2006;345(4):1386–92.CrossRefPubMed
24.
go back to reference Hogan KA, Chini CCS, Chini EN. The multi-faceted ecto-enzyme CD38: roles in immunomodulation, cancer, aging, and metabolic diseases. Front Immunol. 2019;10:1187.CrossRefPubMedPubMedCentral Hogan KA, Chini CCS, Chini EN. The multi-faceted ecto-enzyme CD38: roles in immunomodulation, cancer, aging, and metabolic diseases. Front Immunol. 2019;10:1187.CrossRefPubMedPubMedCentral
25.
go back to reference Latorre I, et al. Study of CD27 and CCR4 markers on specific CD4(+) T-cells as immune tools for active and latent tuberculosis management. Front Immunol. 2018;9:3094.CrossRefPubMed Latorre I, et al. Study of CD27 and CCR4 markers on specific CD4(+) T-cells as immune tools for active and latent tuberculosis management. Front Immunol. 2018;9:3094.CrossRefPubMed
26.
go back to reference Silveira-Mattos PS, et al. Differential expression of activation markers by Mycobacterium tuberculosis-specific CD4+ T cell distinguishes extrapulmonary from pulmonary tuberculosis and latent infection. Clin Infect Dis. 2020;71(8):1905–11.CrossRefPubMed Silveira-Mattos PS, et al. Differential expression of activation markers by Mycobacterium tuberculosis-specific CD4+ T cell distinguishes extrapulmonary from pulmonary tuberculosis and latent infection. Clin Infect Dis. 2020;71(8):1905–11.CrossRefPubMed
27.
go back to reference Xu F, et al. Assessment of CD27 expression on T-cells as a diagnostic and therapeutic tool for patients with smear-negative pulmonary tuberculosis. BMC Immunol. 2021;22(1):41.CrossRefPubMedPubMedCentral Xu F, et al. Assessment of CD27 expression on T-cells as a diagnostic and therapeutic tool for patients with smear-negative pulmonary tuberculosis. BMC Immunol. 2021;22(1):41.CrossRefPubMedPubMedCentral
28.
29.
go back to reference Stelianides S, Belmatoug N, Fantin B. Manifestations and diagnosis of extrapulmonary tuberculosis. Rev Mal Respir. 1997;14(Suppl 5):S72-87.PubMed Stelianides S, Belmatoug N, Fantin B. Manifestations and diagnosis of extrapulmonary tuberculosis. Rev Mal Respir. 1997;14(Suppl 5):S72-87.PubMed
30.
go back to reference Eurosurveillance Editorial Team. WHO revised definitions and reporting framework for tuberculosis. Euro Surveill. 2013;18(16):20455. Eurosurveillance Editorial Team. WHO revised definitions and reporting framework for tuberculosis. Euro Surveill. 2013;18(16):20455.
31.
go back to reference WHO. Latent tuberculosis infection updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. 2018. WHO. Latent tuberculosis infection updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. 2018.
32.
go back to reference Ahmed MIM, et al. Phenotypic changes on Mycobacterium tuberculosis-specific CD4 T cells as surrogate markers for tuberculosis treatment efficacy. Front Immunol. 2018;9:2247.CrossRefPubMedPubMedCentral Ahmed MIM, et al. Phenotypic changes on Mycobacterium tuberculosis-specific CD4 T cells as surrogate markers for tuberculosis treatment efficacy. Front Immunol. 2018;9:2247.CrossRefPubMedPubMedCentral
Metadata
Title
Evaluation of Mycobacterium tuberculosis specific antigen-stimulated CD27−CD38+IFN-γ+CD4+ T cells for discrimination of active tuberculosis
Authors
Yong Fang
Na Wang
Liang Tang
Xiao-Jun Yang
Yuan Tang
Lin Li
Wen-Fei Wu
Bo Su
Wei Sha
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07895-1

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.